This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
by Sanghamitra Saha
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
What Makes Minerva Neurosciences (NERV) a New Buy Stock
by Zacks Equity Research
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
by Zacks Equity Research
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
by Zacks Equity Research
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.
Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
by Zacks Equity Research
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
by Zacks Equity Research
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
by Zacks Equity Research
AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
by Zacks Equity Research
The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.
Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I
by Zacks Equity Research
Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
Minerva Neurosciences (NERV) Enters Overbought Territory
by Zacks Equity Research
Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
Minerva (NERV) Soars on Promising Schizophrenia Study Data
by Zacks Equity Research
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?
by Zacks Small-Cap Research
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.